If CD19 CAR T-Cell Therapy Doesn't Work in Lymphoma, Consider a CD22 Option
— Potential for durable responses with alternative antigen-targeted therapy A promising new treatment targeting a different antigen has shown success among patients with large B-cell lymphoma who previously relapsed after receiving CD19-directed CAR T-cell therapy (CAR19), according to findings from a phase I dose-finding study. In the study, 38 patients who had not responded to CAR19 achieved a 68% overall response rate and a 53% complete response rate following treatment with autologous
278 likes
10 788 views
